查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010927

脑肿瘤治疗市场：2026-2032年全球市场预测（依适应症、药物类别、给药途径、最终用户及通路划分）

Brain Cancer Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，脑肿瘤治疗市场价值将达到 23.4 亿美元，到 2026 年将成长至 25.1 亿美元，到 2032 年将达到 39.3 亿美元，复合年增长率为 7.66%。

主要市场统计数据
基准年 2025 23.4亿美元
预计年份：2026年 25.1亿美元
预测年份 2032 39.3亿美元
复合年增长率 (%) 7.66%

本文概述了在科学和商业性快速变革的背景下，脑肿瘤治疗的当前策略格局。

本文将脑肿瘤治疗定位为肿瘤学领域的首要关注点，这主要源自于亟待满足的迫切需求和加速发展的科学创新。临床复杂性、血脑障壁挑战、诊断异质性以及监管要求等因素共同导致转化研究的成功需要分子生物学、递送技术和临床试验设计等方面的综合能力。近年来，脑肿瘤治疗的手段不断拓展，从细胞毒性药物扩展到生物製药、细胞疗法以及旨在调节肿瘤微环境和免疫反应的标靶小分子化合物。

脑肿瘤治疗的治疗方法和商业模式将发生重大变革。

近年来，多项变革性变化改变了研发人员、临床医生和支付方对脑肿瘤治疗的认知。精准肿瘤学已从概念走向实践，分子谱分析能够识别可治疗的突变并指南患者选择策略，从而改变了临床试验设计，并实现了主导生物标誌物的适应症。同时，免疫疗法技术日益成熟，癌症疫苗、CAR-T疗法和查核点抑制剂等疗法正在中枢神经系统疾病的治疗中进行测试。这些技术促使人们重新思考联合治疗以及适用于免疫机制的新型终点指标。

评估 2025 年美国关税对脑肿瘤治疗的供应链、定价和策略采购的累积影响。

关税的实施为跨境供应链中的製药企业、契约製造和经销商带来了新的考量。关税的变化会改变从国际供应商采购的活性成分和辅料的相对成本结构，促使企业重新评估其供应商多元化、近岸外包和库存策略。由于许多脑肿瘤治疗依赖特殊的原料、生物成分或医疗设备相关的给药系统，即使投入成本略有增加，也可能对生产计划和合约定价结构产生连锁反应。

透过按适应症、药物类别、给药途径、最终用户和分销管道进行细分所获得的见解，可以帮助制定策略重点。

基于适应症的细分揭示了临床需求和研发重点的异质性。胶质母细胞瘤由于其高度侵袭性的生物学特性，仍存在未满足的医疗需求；而脑膜瘤、转移性脑瘤和脑下垂体瘤则各自需要不同的治疗方法和监管途径。了解这些临床差异有助于明确标靶选择和临床试验设计。基于药物类别的细分錶明，化疗仍然是某些治疗方法的基础支柱，其中烷化剂、抗代谢药物和植物生物碱发挥细胞毒性作用。同时，癌症疫苗、CAR-T疗法和查核点抑制剂等免疫疗法提供了免疫介导的策略，可以为特定患者群体带来持续的疗效。支持疗法，例如止吐药和生长因子，在维持剂量强度和保护患者的生活品质方面发挥至关重要的作用。标靶治疗，包括单株抗体和蛋白酪氨酸激酶抑制剂，能够精准标靶化致癌性驱动因子和讯号通路。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和竞争格局影响着市场进入和合作策略。

由于法律规范、报销系统、临床研究能力和医疗基础设施的差异，区域趋势差异显着。在美洲，成熟的高品质医疗中心和强大的临床试验网络支持新疗法的早期引入并促进患者快速入组，同时支付方也越来越重视真实世界疗效证据。在欧洲、中东和非洲，监管协调和国家卫生技术评估流程的推进需要周密的市场准入规划和长期的卫生经济模型，以确保新疗法能够被纳入处方药目录。在亚太地区，对癌症研究的快速投入、医院容量的扩充以及本地生产能力的提升，为扩大规模提供了机会，但也带来了监管路径和定价环境多样性带来的复杂性。

深入了解推动脑肿瘤治疗进步的公司层面能力、策略定位和合作模式。

领先的製药和生物技术公司正在多个领域加强自身能力，以保持脑肿瘤治疗领域的成长动能。研发投入日益集中于增强中枢神经系统穿透性的平台、基于生物标记的患者筛选以及标靶治疗与免疫调节剂联合应用的策略。除了病毒载体和细胞疗法等专业生产能力外，各公司还透过与诊断开发公司合作，共同开发伴随诊断检测，从而实现精准的患者招募和适应症区分，以此来提升自身竞争力。

为产业领导者提供切实可行的建议，以加强开发平臺、市场进入和以病人为中心的服务模式。

行业领导者应优先考虑与监管机构和保险公司进行早期且反覆的对话，以就证据要求和能够反映切实临床获益的可接受终点达成一致。投资于伴随诊断和标准化生物标记检测将提高临床实验临床实验的效率，并支持针对特定适应症的索赔。从营运角度来看，提高供应链冗余度并寻求区域性生产伙伴关係，可以在降低关税和物流风险的同时，缩短临床试验週期。

本报告提供了透明的调查方法，解释了资料来源、分析方法以及支持研究结果的检验过程。

本调查方法整合了第一手调查和第二手调查，以确保研究结果的全面性和有效性。第一手调查包括对临床研究人员、肿瘤药剂师、保险公司、医院采购负责人和行业高管进行结构化访谈，并辅以咨询委员会的咨询，以了解临床实践模式和推广应用障碍。第二手调查包括同行评审文献、监管文件、临床试验註册信息、会议论文集和公司资讯披露，以了解技术趋势、作用机制的进展和监管先例。

全面概述脑肿瘤治疗领域相关人员的临床预期、商业性现实和策略挑战。

总之，目前脑瘤治疗的现况呈现出科学界对治疗寄予厚望，但研发和商业化过程中却面临许多复杂挑战的局面。精准医疗、免疫疗法和递送技术的进步拓展了有前景的治疗策略范围，但要将其广泛应用于临床实践，需要在临床开发、诊断、生产和医保支付方合作等方面做出协调一致的努力。供应链压力和关税趋势要求企业采取策略性采购策略，并考虑区域性生产。同时，不同地区监管环境和报销机制的差异也要求企业采取个人化的市场进入策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：脑肿瘤治疗市场：依适应症划分

  • 多形性胶质母细胞瘤
  • 脑膜瘤
  • 转移性脑瘤
  • 脑下垂体瘤

第九章：脑肿瘤治疗市场：依药物类别划分

  • 化疗
    • 烷化剂
    • 抗代谢物
    • 植物生物碱
  • 免疫疗法
    • 癌症疫苗
    • CAR-T疗法
    • 查核点抑制剂
  • 支持性护理
    • 止吐药
    • 生长因子
  • 分子标靶治疗
    • 单株抗体
    • 蛋白酪氨酸激酶抑制剂

第十章：脑肿瘤治疗市场：依给药途径划分

  • 鞘内腔
  • 静脉注射
  • 口服

第十一章：脑肿瘤治疗市场：依最终用户划分

  • 诊所
  • 家庭医疗保健
  • 医院

第十二章：脑肿瘤治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：脑肿瘤治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：脑肿瘤治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 脑肿瘤治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国脑肿瘤治疗市场

第十七章：中国脑肿瘤治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Arbor Pharmaceuticals, LLC
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation（a Bristol-Myers Squibb company）
  • DNAtrix, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Ipsen SA
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc.
  • Kazia Therapeutics Limited
  • Merck KGaA
  • Mundipharma International Limited
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-434CCDA05263

The Brain Cancer Drugs Market was valued at USD 2.34 billion in 2025 and is projected to grow to USD 2.51 billion in 2026, with a CAGR of 7.66%, reaching USD 3.93 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.34 billion
Estimated Year [2026] USD 2.51 billion
Forecast Year [2032] USD 3.93 billion
CAGR (%) 7.66%

Framing the Current Strategic Context for Brain Cancer Therapeutics Amid Rapid Scientific and Commercial Change

The introduction positions brain cancer drugs as a high-priority area within oncology, driven by an urgent unmet medical need and accelerating scientific innovation. Clinical complexity, blood-brain barrier challenges, diagnostic heterogeneity, and regulatory expectations together create a landscape where translational success requires integrated capabilities across molecular biology, delivery technologies, and clinical trial design. Recent advances have expanded the therapeutic toolkit beyond cytotoxic agents to include biologics, cell therapies, and targeted small molecules that aim to modulate tumor microenvironments and immune responses.

From a commercial perspective, stakeholders must balance high development costs and protracted clinical pathways with the potential for durable clinical benefit in select patient populations. Payers and health technology assessment bodies are increasingly focused on real-world evidence and value-based contracting, which places a premium on post-approval evidence generation and adaptive reimbursement arrangements. Consequently, strategic planning now emphasizes diversified portfolios, earlier engagement with regulators and payers, and investment in companion diagnostics and novel delivery platforms to maximize the probability of clinical and commercial success.

Taken together, the introduction highlights the dual imperative: advancing cutting-edge science while pragmatically addressing commercialization, access, and delivery challenges to ensure that innovations translate into meaningful patient outcomes.

Major Transformative Shifts Redefining Treatment Approaches and Commercial Models Across Brain Cancer Therapeutics

Over recent years, several transformative shifts have altered how developers, clinicians, and payers approach brain cancer drugs. Precision oncology has moved from concept to practice as molecular profiling identifies actionable alterations and informs patient selection strategies, thereby changing clinical trial designs and enabling biomarker-driven indications. Concurrently, immunotherapeutic modalities have matured, with cancer vaccines, CAR-T approaches, and checkpoint inhibitors being tested in central nervous system indications; these modalities have prompted reconsideration of combination regimens and novel endpoints suited to immunologic mechanisms.

At the same time, targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, have adapted to constraints imposed by the blood-brain barrier through innovative formulation strategies and delivery tools, which include both systemic modifications and localized administration methods. Supportive therapies, such as anti-emetics and growth factors, have become integral to comprehensive patient management, improving tolerability and enabling sustained delivery of primary agents. The role of digital health, advanced imaging, and liquid biopsies has also expanded, enabling more dynamic monitoring of disease trajectory and therapy response. Collectively, these shifts demand new operational models, collaborative ecosystems with diagnostic partners, and an increased emphasis on post-market evidence generation to demonstrate long-term benefit and value.

Assessing the Cumulative Impact of United States Tariffs in 2025 on Supply Chains, Pricing, and Strategic Sourcing in Brain Cancer Therapeutics

The imposition of tariffs has introduced new considerations for pharmaceutical manufacturers, contract manufacturers, and distributors that operate across transnational supply chains. Tariff changes can alter the relative cost structure of active pharmaceutical ingredients and excipients sourced from international suppliers, prompting firms to reassess supplier diversification, nearshoring, and stockpiling strategies. For brain cancer therapeutics-many of which rely on specialized raw materials, biologic components, or device-related delivery systems-any incremental input cost can cascade through manufacturing schedules and contractual pricing structures.

Moreover, tariffs have implications for clinical trial logistics and the movement of investigational medicinal products between study sites, potentially increasing administrative overhead and necessitating earlier contingency planning. Payers and procurement teams may respond to altered cost baselines by tightening formularies or emphasizing cost-effectiveness data, which underscores the importance of demonstrating differential clinical value. In response, industry players are pursuing strategies such as renegotiating supplier agreements, transferring select manufacturing steps to tariff-favored jurisdictions, and accelerating localization of critical inputs. Ultimately, the net effect is an increased premium on supply chain resilience and strategic sourcing decisions, with successful organizations prioritizing flexibility and transparent cost modeling to mitigate tariff-driven disruptions.

Insights Derived from Segmentation by Indication, Drug Class, Administration Route, End User, and Distribution Channel That Inform Strategic Priorities

Segmentation by indication clarifies heterogeneity in clinical need and development emphasis, with glioblastoma multiforme representing persistent unmet needs due to its aggressive biology, while meningioma, metastatic brain tumors, and pituitary tumors each require distinct therapeutic approaches and regulatory pathways. Understanding those clinical distinctions sharpens target selection and trial design. Segmentation by drug class highlights that chemotherapy remains a foundational backbone in some regimens, with alkylating agents, antimetabolites, and plant alkaloids delivering cytotoxic mechanisms. Meanwhile, immunotherapy modalities such as cancer vaccines, CAR-T therapy, and checkpoint inhibitors offer immune-mediated strategies that may provide durable responses in selected cohorts. Supportive therapy components like anti-emetics and growth factors play a critical role in maintaining dose intensity and patient quality of life. Targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, enable precision targeting of oncogenic drivers and signaling pathways.

Route of administration segmentation-intrathecal, intravenous, and oral-drives considerations around formulation development, patient adherence, and facility requirements, and it informs decisions on outpatient versus inpatient delivery models. End user segmentation across clinics, home healthcare, and hospitals shapes operational planning for infusion capacity, home administration protocols, and training needs for multidisciplinary teams. Distribution channel segmentation differentiates hospital pharmacies, online pharmacies, and retail pharmacies, each presenting unique compliance, cold chain, and reimbursement touchpoints that influence market access strategies. By integrating these segment lenses, stakeholders can prioritize resource allocation, refine clinical development plans, and align commercialization approaches with the operational realities of delivery and access.

Regional Dynamics and Competitive Contexts Across the Americas, Europe, Middle East & Africa, and Asia-Pacific That Shape Market Entry and Partnership Strategies

Regional dynamics vary substantially, driven by differences in regulatory frameworks, reimbursement architectures, clinical research capacity, and healthcare infrastructure. In the Americas, established centers of excellence and robust clinical trial networks support early adoption of novel therapeutics and facilitate rapid patient accrual, while payers increasingly demand real-world outcome evidence. In Europe, Middle East & Africa, regulatory harmonization efforts and national health technology assessment processes require nuanced market access planning and long-term health economic modeling to secure formulary inclusion. In Asia-Pacific, rapid investments in oncology research, expanding hospital capacity, and growing local manufacturing capabilities present both scale opportunities and complexity related to heterogeneous regulatory pathways and pricing environments.

Across these regions, partnership models differ: collaborations with academic centers and contract research organizations support translational research in advanced markets, while alliances with regional distributors and local manufacturers enable market entry where localized production or regulatory familiarity is advantageous. Clinical adoption is influenced by variations in diagnostic capacity and standard-of-care practices, which can affect the pace of uptake for biomarker-driven therapies. Therefore, region-specific strategies that consider regulatory timing, reimbursement levers, and local clinical practice are essential for effective deployment of brain cancer therapeutics.

Key Company-Level Insights on Capabilities, Strategic Positioning, and Collaboration Models Driving Progress in Brain Cancer Therapeutics

Leading pharmaceutical and biotechnology companies are strengthening capabilities across several domains to sustain momentum in brain cancer therapeutics. R&D investments are increasingly concentrated on platforms that enhance central nervous system penetration, biomarker-driven patient selection, and combination strategies that pair targeted agents with immune modulators. Companies are differentiating through specialized manufacturing competencies, including viral vector and cell therapy production, as well as through strategic partnerships with diagnostic developers to co-develop companion assays that enable precise enrollment and label differentiation.

Collaboration models show a clear trend toward risk-sharing alliances between innovators, contract manufacturing organizations, academic centers, and biotechnology partners. These models facilitate access to niche expertise, accelerate early-phase development, and de-risk later-stage programs. Portfolio strategies favor a balance between novel mechanisms of action and assets that enhance tolerability or extend durability of response. Additionally, business development activity increasingly emphasizes in-licensing of promising early-stage assets and targeted acquisitions that complement delivery technologies or diagnostic capabilities. Overall, successful organizations demonstrate integrated clinical, regulatory, and commercial planning supported by strategic external partnerships.

Actionable Recommendations for Industry Leaders to Strengthen Development Pipelines, Market Access, and Patient-Centered Delivery Models

Industry leaders should prioritize early and iterative engagement with regulatory agencies and payers to align on evidence requirements and acceptable end points that reflect meaningful clinical benefit. Investing in companion diagnostics and standardized biomarker assays will improve trial efficiency and support targeted labeling claims. From an operational perspective, enhancing supply chain redundancy and pursuing regional manufacturing partnerships can mitigate tariff and logistic risks while shortening time-to-clinic for investigational products.

Companies should also design development programs that build robust real-world evidence pathways, including registries and post-approval studies, to support durable reimbursement agreements. Emphasizing tolerability and quality-of-life outcomes alongside efficacy will aid in demonstrating value to clinicians and payers. Collaboration with home healthcare providers and hospitals to develop safe administration protocols will expand access and reduce treatment burden for patients. Finally, adopting flexible commercial models-such as outcome-linked contracting and tailored regional pricing strategies-can facilitate access across diverse healthcare systems while protecting commercial sustainability.

Transparent Research Methodology Explaining Data Sources, Analytic Approaches, and Validation Processes That Underpin the Report's Findings

The research methodology integrates primary and secondary approaches to ensure comprehensive coverage and validation of insights. Primary research comprises structured interviews with clinical investigators, oncology pharmacists, payers, hospital procurement officers, and industry executives, supplemented by advisory board consultations to contextualize practice patterns and adoption barriers. Secondary research includes peer-reviewed literature, regulatory documents, clinical trial registries, conference proceedings, and company disclosures to map technological trends, mechanism of action developments, and regulatory precedents.

Analytical techniques include qualitative thematic analysis to synthesize stakeholder perspectives and quantitative cross-sectional analyses to examine adoption patterns across segments and regions. Triangulation of data sources and iterative validation with subject-matter experts are employed to reduce bias and confirm findings. The methodology acknowledges limitations related to the evolving clinical landscape and potential lag between emerging scientific developments and peer-reviewed evidence, and it emphasizes that conclusions are intended to inform strategic decision-making rather than provide prescriptive clinical guidance.

Concluding Synthesis That Integrates Clinical Promise, Commercial Realities, and Strategic Imperatives for Brain Cancer Drug Stakeholders

In conclusion, the brain cancer therapeutics landscape is characterized by significant scientific promise alongside complex developmental and commercialization challenges. Advances in precision medicine, immunotherapy, and delivery science have expanded the array of plausible therapeutic strategies, but successful translation into widespread clinical practice requires coordinated efforts across clinical development, diagnostics, manufacturing, and payer engagement. Supply chain pressures and tariff dynamics have added urgency to strategic sourcing and regional manufacturing considerations, while regional heterogeneity in regulatory and reimbursement systems demands tailored market access approaches.

To capitalize on emerging opportunities, organizations must combine scientific rigor with pragmatic commercial planning: design biomarker-enabled trials, invest in companion diagnostics and real-world evidence, strengthen manufacturing and distribution resilience, and pursue collaborative alliances that bring complementary capabilities. By aligning clinical innovation with operational excellence and payer-focused evidence generation, stakeholders can improve patient access to meaningful treatments and create sustainable value across the therapeutic ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Cancer Drugs Market, by Indication

  • 8.1. Glioblastoma Multiforme
  • 8.2. Meningioma
  • 8.3. Metastatic Brain Tumors
  • 8.4. Pituitary Tumors

9. Brain Cancer Drugs Market, by Drug Class

  • 9.1. Chemotherapy
    • 9.1.1. Alkylating Agents
    • 9.1.2. Antimetabolites
    • 9.1.3. Plant Alkaloids
  • 9.2. Immunotherapy
    • 9.2.1. Cancer Vaccines
    • 9.2.2. CAR-T Therapy
    • 9.2.3. Checkpoint Inhibitors
  • 9.3. Supportive Therapy
    • 9.3.1. Anti-Emetics
    • 9.3.2. Growth Factors
  • 9.4. Targeted Therapy
    • 9.4.1. Monoclonal Antibodies
    • 9.4.2. Tyrosine Kinase Inhibitors

10. Brain Cancer Drugs Market, by Route Of Administration

  • 10.1. Intrathecal
  • 10.2. Intravenous
  • 10.3. Oral

11. Brain Cancer Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals

12. Brain Cancer Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Brain Cancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Brain Cancer Drugs Market

17. China Brain Cancer Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. Arbor Pharmaceuticals, LLC
  • 18.8. AstraZeneca PLC
  • 18.9. Bayer AG
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Celgene Corporation (a Bristol-Myers Squibb company)
  • 18.12. DNAtrix, Inc.
  • 18.13. Eli Lilly and Company
  • 18.14. F. Hoffmann-La Roche Ltd
  • 18.15. Ipsen SA
  • 18.16. Johnson & Johnson
  • 18.17. Karyopharm Therapeutics Inc.
  • 18.18. Kazia Therapeutics Limited
  • 18.19. Merck KGaA
  • 18.20. Mundipharma International Limited
  • 18.21. Novartis AG
  • 18.22. Novocure GmbH
  • 18.23. Pfizer Inc.
  • 18.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. GCC BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. G7 BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. G7 BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. G7 BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. G7 BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. G7 BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. NATO BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. NATO BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. NATO BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. NATO BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)